&w=3840&q=100)
Alembic Pharma receives USFDA approval for generic hypertension drug
The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement.
These are therapeutically equivalent to the reference-listed drug product, Caduet tablets of corresponding strengths of Pharmacia and Upjohn Co LLC, it added.
Alembic said it has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from the USFDA.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
an hour ago
- Business Standard
Zydus Lifesciences receives four observations from USFDA following inspection at Himachal Pradesh facility
Zydus Lifesciences announced that its formulation manufacturing facility located in Baddi, Himachal Pradesh, has received four observations from the United States Food and Drug Administration (USFDA). According to an exchange filing, the company stated that the USFDA concluded a surveillance inspection at the Baddi facility, which was conducted from 4 August to 13 August 2025. The inspection ended with four observations. The company clarified that none of the observations were related to data integrity. Zydus added that it will work closely with the USFDA to address and resolve the observations expeditiously. In a separate filing, the company also informed that the USFDA conducted a Pre-Approval Inspection (PAI) at its formulation manufacturing facility located in SEZ II, Ahmedabad. The inspection, which covered three products and general current Good Manufacturing Practices (cGMP), was conducted from 11 August to 13 August 2025. This inspection concluded with no observations, indicating a clean outcome. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 1% to Rs 1,170.90 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. The counter added 1.35% to end at Rs 1,002.40 on the BSE.
News18
2 hours ago
- News18
Amansa Investments pumps Rs 250 cr in Rubicon Research in pre-IPO funding round
New Delhi, Aug 14 (PTI) Amansa Investments Ltd has invested Rs 250 crore in pharma formulation firm Rubicon Research Ltd through a pre-initial public offering (IPO) funding round. As part of the transaction, General Atlantic Singapore RR Pte Ltd, one of Rubicon Research's promoters, transferred 51.60 lakh equity shares to Amansa Investments at Rs 484.47 per share, amounting to Rs 250 crore, the company said in a public announcement. At the time of filing draft papers in July 2024, General Atlantic held 8.89 crore equity shares, representing a 57.57 per cent stake. Following the pre-IPO deal, it will hold 8.37 crore equity shares, or 54.01 per cent of the company. The transaction, conducted in consultation with the book running lead managers (BRLMs) of Rubicon Research, received board approval on August 12. Other promoters of the company include Pratibha Pilgaonkar, Sudhir D Pilgaonkar, Parag S Sancheti, Surabhi P Sancheti, and Sumant S Pilgaonkar. Rubicon Research's proposed IPO consisted of a fresh issue of equity shares worth Rs 500 crore alongside an offer-for-sale of shares valued Rs 585 crore. Following the latest fundraise, the size of the fresh issue has been reduced by Rs 250 crore. The company plans to utilise proceeds from the fresh issue for payment of debt, supporting inorganic growth through unidentified acquisitions as well as other strategic initiatives and general corporate purposes. The pharma firm has two US FDA-inspected research and development (R&D) facilities, one each in India and Canada, and two manufacturing facilities in India with multiple accreditations from multiple regulatory agencies such as USFDA, Food and Drugs Administration, Maharashtra (WHO-GMP accreditation) and Health Canada. As on March 31, 2024, Rubicon Research had a portfolio of 69 products approved by the USFDA, 19 new drugs awaiting USFDA's nod and 46 products in various stages of development. PTI SP DRR view comments First Published: August 14, 2025, 12:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Standard
a day ago
- Business Standard
Indoco Remedies gains on receiving USFDA nod for Rivaroxaban tablets
Indoco Remedies rose 1.56% to Rs 296.15 after the company announced it had received final approval from the USFDA for its ANDA for Rivaroxaban tablets USP. The approval covers strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The approved tablets are bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Xarelto Tablets, manufactured by Janssen Pharmaceuticals, Inc. The product will be manufactured at Indocos facility in Verna Industrial Area, Goa (L-14, Verna, Goa 403722). Rivaroxaban is an oral anticoagulant used for the treatment and prevention of venous thromboembolism (VTE) a serious condition involving blood clots in the veins, which can lead to complications such as pulmonary embolism. Commenting on the development, Aditi Panandikar, managing director of Indoco Remedies, said, Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US. Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company had reported a consolidated net loss of Rs 40.39 crore in the quarter ended March 2025 as against net profit of Rs 22.70 crore during the previous quarter ended March 2024. Sales declined by 12.57% to Rs 383.89 crore in Q4 FY25 over Q4 FY24.
